Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam.
about
K13 Propeller Mutations in Plasmodium falciparum Populations in Regions of Malaria Endemicity in Vietnam from 2009 to 2016.Combating multidrug-resistant Plasmodium falciparum malaria.Challenges to replace ACT as first-line drug.Profiling molecular factors associated with pyknosis and developmental arrest induced by an opioid receptor antagonist and dihydroartemisinin in Plasmodium falciparum.Malaria risk factors and care-seeking behaviour within the private sector among high-risk populations in Vietnam: a qualitative study.Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence.The prevalence, incidence and prevention of Plasmodium falciparum infections in forest rangers in Bu Gia Map National Park, Binh Phuoc province, Vietnam: a pilot study.Plasmodium falciparum Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar.Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study.Plasmepsins on the antimalarial hit list.Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination.Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum.Rapamycin promotes the anticancer action of dihydroartemisinin in breast cancer MDA-MB-231 cells by regulating expression of Atg7 and DAPK.The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African Plasmodium falciparum isolates.Comparison of the Pharmacokinetics and Ex Vivo Antimalarial Activities of Artesunate-Amodiaquine and Artemisinin-Piperaquine in Healthy Volunteers for Preselection Malaria Therapy.Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar.Characterization of Plasmodium falciparum and Plasmodium vivax recent exposure in an area of significantly decreased transmission intensity in Central Vietnam.Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum.Drugs in Development for Malaria.Effectiveness and safety of 3 and 5 day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar.Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquineArtemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium falciparum Transmissible Gametocyte StagesEfficacy of artemisinin-based combination therapies and prevalence of molecular markers associated with artemisinin, piperaquine and sulfadoxine-pyrimethamine resistance in Sierra LeoneMalariaEmerging implications of policies on malaria treatment: genetic changes in the gene affecting susceptibility to artemether-lumefantrine and artesunate-amodiaquine in Africa
P2860
Q37720813-3C3BA58B-D2F1-42FA-8E4D-6A06DE66ECD8Q39350422-2D4AB0CA-00C6-4DE6-96BE-FD8F1247ACE9Q39354871-E0F68A91-655E-4A4D-929C-8E0245F2E947Q41995638-038DA80A-552D-4392-B880-4F12600A223EQ42379272-0553AC3F-6660-4EAA-8AB4-34F3883C3F10Q43923927-1C04690B-DFF4-42C0-A53E-FE744BB7C4CCQ47111312-3340F275-A588-49BB-8A7F-1B02889B01F0Q47142321-7DDCDDD2-24B0-4B37-AF0D-1E0E95A4A97FQ48506962-9A662D45-7056-4C61-AB76-B80AFAC0D52AQ50092308-8D206ACC-B200-45DF-AEDA-0B5243650877Q52575118-9482F533-9752-4C79-B93E-6365F38987D0Q52615236-9A97C378-2657-4F81-986D-1D32910E26AFQ52646479-E834E662-63FA-43E8-8E4A-7D6EE70234A8Q52653027-8A133BA7-4530-440C-BD93-8956E8849CB6Q52660184-13528FBE-7FED-4B79-878D-53F8B8606B30Q53685504-E880AD7A-765D-4EBE-B378-66DFBF54E89CQ54250760-CB1FF7A5-F15B-46D4-8410-A42315655283Q54961584-6EB7C207-02F8-4297-9BF6-0BA0D3CA0762Q55001227-54F4E8C3-C418-419E-A655-1C51C7DE08BAQ55278895-353604B2-E49E-4E7E-889D-0F6ADAB967BAQ55711310-4ED411D4-39DD-43F4-A763-D5ACFB798698Q56342194-1A3C3BC9-5CC6-47F0-A6A2-0CBA7717EDDDQ56355670-C3D5FE88-5F70-41EF-85EC-5BF69E80E5B4Q56376468-BC23CB9A-EBDF-43F5-B2EF-B5B53FABFB76Q56378965-B7AB6472-9204-432C-BF1F-4C0F15CEEC4CQ58586501-8FC3C8E2-75AB-4C70-B497-3F3FC631C95F
P2860
Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rapid decline in the susceptib ...... quine in the south of Vietnam.
@en
Rapid decline in the susceptib ...... quine in the south of Vietnam.
@nl
type
label
Rapid decline in the susceptib ...... quine in the south of Vietnam.
@en
Rapid decline in the susceptib ...... quine in the south of Vietnam.
@nl
prefLabel
Rapid decline in the susceptib ...... quine in the south of Vietnam.
@en
Rapid decline in the susceptib ...... quine in the south of Vietnam.
@nl
P2093
P2860
P50
P1433
P1476
Rapid decline in the susceptib ...... quine in the south of Vietnam.
@en
P2093
Huynh Hong Quang
Le Thanh Dong
Ngo Viet Thanh
Nguyen Thanh Tong
Nguyen Thi Kim Tuyen
Nguyen Thuy Nha-Ca
P2860
P2888
P356
10.1186/S12936-017-1680-8
P50
P577
2017-01-13T00:00:00Z
P6179
1051917677